Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma
Public ClinicalTrials.gov record NCT01233375. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Open-Label, Multicenter Study to Evaluate the Antitumor Efficacy of CO-1.01 for Infusion as Second-Line Therapy for Gemcitabine- Refractory Patients With Stage IV Pancreatic Adenocarcinoma and No Tumor hENT1 Expression
Study identification
- NCT ID
- NCT01233375
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Clovis Oncology, Inc.
- Industry
- Enrollment
- 19 participants
Conditions and interventions
Conditions
Interventions
- CO-1.01 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2011
- Primary completion
- Feb 28, 2013
- Completion
- Feb 28, 2013
- Last update posted
- Mar 10, 2019
2011 – 2013
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Cancer Center at University of Arizona | Tucson | Arizona | 85724 | — |
| Rocky Mountain Cancer Center | Denver | Colorado | 80218 | — |
| Palm Beach Institute / Collaborative Research Group | Boynton Beach | Florida | 33425 | — |
| University of Miami | Miami | Florida | 33136 | — |
| Piedmont Healthcare Research Institute (PHRI) | Atlanta | Georgia | 30309 | — |
| Norton Cancer Institute Research Program | Louisville | Kentucky | 40202 | — |
| Johns Hopkins Oncology Center | Baltimore | Maryland | 21231 | — |
| Massachusetts General Hospital (MGH) | Boston | Massachusetts | 02114 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10021 | — |
| Columbia University Medical Center, Milstein Hospital | New York | New York | 10032 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| University of Pittsburgh Cancer Institute | Pittsburgh | Pennsylvania | 15232-1305 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01233375, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 10, 2019 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01233375 live on ClinicalTrials.gov.